2minutemedicine

Pfizer and Innovent deepen the China biotech licensing wave Pfizer is making another large oncology bet, this time through a broad collaboration with Innovent Biologics that could be worth up to $10.5 billion. The agreement includes $650 million upfront and covers 12 early stage cancer programs, including antibody drug conjugates and multispecific antibodies. That mix […]

1. The Canadian Syncope Risk Score (CSRS) and FAINT score are effective at identifying which adult patients presenting to the emergency department (ED) are at low risk for short-term adverse outcomes. Evidence Rating Level: 2 (Good) Syncope and presyncope account for 2-3% of all ED visits, with approximately 10% of these patients having serious underlying […]

1. Incorporating procalcitonin-guided decision making in the management of neonatal late-onset sepsis significantly reduced the duration of antibiotic treatment without increasing mortality. Evidence Rating Level: 1 (Excellent) Late-onset neonatal sepsis, defined as sepsis occurring after 72 hours of life, is a common neonatal disease. However, the optimal duration of antimic...

1. H3-10353, a novel γ-aminobutyric acid (GABA) positive allosteric modulator, is safe and well-tolerated in healthy patients and those with major depressive disorder (MDD), and demonstrated some therapeutic benefits in a phase 1 clinical trial. Evidence Rating Level: 1 (Excellent) Although there are numerous classes of medications for depression, these treatments result in r...

1. Adding a thrombolytic agent delivered through the arterial catheter immediately following mechanical clot extraction increased near-complete functional recovery at three months. 2. Rates of symptomatic brain bleeding did not differ meaningfully between groups, but three-month mortality was significantly higher in the combination arm. Evidence Rating Level: 1 (Excellent) St...